What type of study is this?

This is a Pre-Registered Trial study.

December 8, 2025BloodOpen Access

Rheological effects of voxelotor in SCD: A double-edged sword?

View Full Paper

Ask AI

Bookmark

Authors

Double-edged sword as Voxelotor improves RBC properties but raises viscosity, suggesting a VOC risk in SCD patients.

Hemoglobin levels increased to 9 g/dL after 12 months, indicating Voxelotor’s effectiveness during treatment.
Significant increases in the hematocrit-to-viscosity ratio were observed, which may relate to improved microvascular function.
Observational analysis assessed rheological parameters in SCD patients, revealing improved RBC deformability and aggregation.
This study highlights the need for careful viscosity monitoring to balance benefits against increased VOC risk.

Luna et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark